Effect of sublingual administration of interferon-α on the immune response to influenza vaccination in institutionalized elderly individuals

Vaccine

Volumn 26, Issue 32, 2008, Pages 4073-4079

  Launay, Odile ^a,b,c   Grabar, Sophie ^a,b   Bloch, Frédéric ^d   Desaint, Corinne ^b,c   Jegou, David ^b   Lallemand, Christophe ^e   Erickson, Robert ^f   Lebon, Pierre ^b   Tovey, Michael G ^e  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b Institut Cochin   (France)

^c INSERM   (France)

^d Paris Descartes University   (France)

^e INSTITUT ANDRÉ LWOFF   (France)

^f Orakine Ltd   (Ireland)

Author keywords

Influenza vaccine; Interferon; The elderly

Indexed keywords

HEMAGGLUTINATION INHIBITING ANTIBODY; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2; IMMUNOGLOBULIN G2A; INFLUENZA VACCINE; PLACEBO; RECOMBINANT ALPHA2B INTERFERON; SECRETORY IMMUNOGLOBULIN;

AGED; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG SAFETY; FEMALE; FEVER; HUMAN; HYPERPLASIA; IMMUNE RESPONSE; IMMUNOGLOBULIN PRODUCTION; INFLAMMATION; INFLUENZA VACCINATION; INFLUENZA VIRUS A; INFLUENZA VIRUS B; INSTITUTIONAL CARE; LEUKOPENIA; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE;

ADMINISTRATION, SUBLINGUAL; AGED; AGED, 80 AND OVER; ANTIBODIES, VIRAL; ANTIGENS, CD26; ANTIGENS, CD30; DOUBLE-BLIND METHOD; FEMALE; HEMAGGLUTINATION INHIBITION TESTS; HUMANS; IMMUNOGLOBULIN A, SECRETORY; IMMUNOGLOBULIN G; INFLUENZA VACCINES; INFLUENZA, HUMAN; INTERFERON-ALPHA; MALE; MOUTH MUCOSA; VACCINATION;

EID: 47149095735     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2008.05.035     Document Type: Article

References (39)

1. Govaert T.M., Thijs C.T., Masurel N., Sprenger M.J., Dinant G.J., and Knottnerus J.A. The efficacy of influenza vaccination in elderly individuals. A randomized double-blind placebo-controlled trial. J Am Med Assoc 272 (1994) 1661-1665
2. McElhaney J.E., Hooton J.W., Hooton N., and Bleackley. Comparison of single versus booster dose of influenza vaccination on humoral and cellular immune responses in older adults. Vaccine 23 (2005) 3294-3300
3. Nichol K.L., Nordin J.D., Nelson D.B., Mullooly J.P., and Hak E. Effectiveness of influenza vaccine in the community-dwelling elderly. N Eng J Med 357 (2007) 137381
4. Steinman R.M., and Hemmi H. Dendritic cells: translating innate to adaptive immunity. Curr. Top. Microbiol. Immunol. 311 (2006) 17-58
5. de Veer M.J., Holko M., Frevel M., Walker E., Der S., Paranjape J.M., et al. Functional classification of interferon-stimulated genes identified using microarrays. J Leukoc Biol 69 (2001) 912-920
6. Le Bon A., Etchart N., Rossmann C., Ashton M., Hou S., Gerwaert D., et al. Cross-priming of CD8+ T cells stimulated by virus-induced type I interferon. Nat Immunol 4 (2003) 1009-1015
7. Le Bon A., Durand V., Kamphuis E., Thompson C., Bulfone-Paus S., Rossmann C., et al. Direct stimulation of T cells by type I IFN enhances CD8+ cell response during cross-priming. J Immunol 176 (2006) 4682-4689
8. Beignon A.S., Skoberne M., and Bhardwaj N. Type I interferons promote cross-priming: more functions for old cytokines. Nat Immunol 4 (2003) 939-941
9. Le Bon A., Schiavoni G., D'Agostino G., Gresser I., Belardelli F., and Tough D.F. Type I interferons potently enhance humoral immunity and can promote isotype switching by stimulating dendritic cells in vivo. Immunity 14 (2001) 461-470
10. Le Bon A., Thompson C., Kamphuis E., Rossmann C., Kalinke U., and Tough D.T. Cutting edge: enhancement of antibody responses through direct stimulation of B and T cells by type I IFN. J Immunol 176 (2006) 2074-2078
11. Jego G., Palucka A.K., Blanck J.-P., Chalouni C., Pascual V., and Banchereau J. Plasmacytoid dendritic cells induce plasma cell differentiation through type I interferon and interleukin 6. Immunity 19 (2003) 225-234
12. Proitti E., Bracci L., Puzelli S., Di Pucchio T., Sestill P., De Vincenzi E., et al. Type I IFN as a natural adjuvant for a productive immune response: lessons from the influenza vaccine model. J Immunol 169 (2002) 375-383
13. Tovey M.G., Lallemand C., Meritet J.-F., and Maury C. Adjuvant activity of interferon alpha: mechanism(s) of action. Vaccine 24 Suppl. 2 (2006) S2-46-47
14. Lien E., and Golenbock D.T. Adjuvants and their signaling pathways: beyond TLRs. Nat Immunol 4 (2003) 1162-1164
15. Tovey MG, Lallemand C, Thyphronitis G, Adjuvant activity of type I interferons. Biol Chem; in press.
16. Rizza P., Capone I., Urbani F., Montefiore E., Rapicetta M., Chionne P., et al. Evaluation of the effects of human leukocyte IFN-alpha on the immune response to the HBV vaccine in healthy unvaccinated individuals. Vaccine 26 (2008) 1038-1049
17. Grob P.J., Joller-Jemelka H.I., Binswagner U., Zaruba K., Descoeudres C., and Fernex M. Interferon as an adjuvant for hepatitis B vaccination in non and low responder populations. Eur J Clin Microbiol 3 (1984) 195-198
18. Goldwater P.N. Randomized comparative trial of interferon-alpha versus placebo in hepatitis B vaccine non-responders and hyporesponders. Vaccine 12 (1994) 410-414
19. Tovey M.G., and Maury C. Oromucosal interferon therapy: marked antiviral and antitumor activity. J Interferon Cytokine Res 19 (1999) 145-155
20. Witt P.L., Goldstein D., Storer B.E., Grossberg S.E., Flashner M., Colby C.B., et al. Absence of biological effects of orally administered interferon beta-ser. J Interferon Res 12 (1992) 411-413
21. Meritet J.-F., Maury C., and Tovey M.G. Induction of tolerance to therapeutic proteins. J Interferon Cytokine Res 21 (2001) 1031-1038
22. Eid P., Meritet J.-F., Maury C., Lasfar A., Weill D., and Tovey M.G. Oromucosal interferon therapy: pharmacokinetics and pharmacodynamics. J Interferon Cytokine Res 19 (1999) 157-169
23. Jarosinski K.W., Jia W., Sekellick M.J., Marcus P.I., and Schat K.A. Cellular responses in chickens treated with IFN-alpha orally or inoculated with Marek's disease virus expression IFN-alpha. J Interferon Cytokine Res 21 (2001) 287-296
24. Marcus P.I., van der Heide L., and Sekellick M. Interferon action on avian viruses. I. Oral administration of chicken interferon-a ameliorates Newcastle disease. J Interferon Cytokine Res 19 (1999) 881-885
25. Beilharz M.W., Cummins J.M., and Bennett A.L. Protection from lethal influenza virus challenge by oral type I interferon. Biochem Biophys Res Commun 355 (2007) 740-744
26. Brod S.A., Nguyen M., Hood Z., and Shiply G.L. Ingested (oral) IFN-alpha represses TNF-alpha mRNA in relapsing-remitting multiple sclerosis. J Interferon Cytokine Res. 26 (2006) 150-155
27. Smith J.K., Siddiqui A.A., Krishnaswamy G.A., Dykes R., Berk S.L., Magee M., et al. Oral use of interferon-a stimulates ISG-15 transcription and production by human buccal epithelial cells. J. Interferon Cytokine Res 19 (1999) 923-928
28. Bosio E., Beilharz M.W., Watson M.W., and Lawson C.M. Efficacy of low-dose oral use of type I interferon in cytomegalovirus infections in vivo. J Interferon Cytokine Res 19 (1999) 869-876
29. Bosio E., Cluning C.L., and Beilharz M.W. Low-dose orally administered type I interferon reduces splenic B cell numbers in mice. J Interferon Cytokine Res 21 (2001) 721-728
30. Lawson C.M., and Beilharz M.W. Low-dose oral use of interferon inhibits virally induced myocarditis. J Interferon Cytokine Res 19 (1999) 863-867
31. Brod S. Autoimmunity is a type I interferon-deficiency syndrome corrected by ingested type I IFN via the GALT system. J Interferon Cytokine Res 19 (1999) 841-852
32. Yang S.S., Fe L.S., Chang C.S., Yeh H.Z., Chen G.H., and Kao J.H. Changes of soluble CD26 and CD30 levels correlate with response to interferon plus ribavirin therapy in patients with chronic hepatitis C. J Gastroenterol Hepatol 21 (2006) 1789-1793
33. Faria A.M., and Weiner H.L. Oral tolerance. Immunol Rev 206 (2005) 232-259
34. Polman C., Barkhof F., Kappos L., Pozzilli C., Sandbrink R., Dahlke F., Jakobs P., et al. Oral interferon beta-1a in relapsing-remitting multiple sclerosis: a double-blind randomized study. Mult Scler 9 (2003) 342-348
35. Peters M., Walling D.M., Kelly K., Davis G.L., Waggoner J.G., and Hoofnagle J.H. Immunologic effects of interferon-alpha in man: treatment with human recombinant interferon-alpha suppresses in vitro immunoglobulin production in patients with chronic type B hepatitis. J Immunol 137 (1986) 3147-3153
36. De Maeyer E., and De Mayer-Guignard J. Nature 284 (1980) 173-175
37. McRae B.L., Nagai T., Semnani R.T., van Seventer J.M., and van Seventer G.A. Interferon-alpha and beta inhibit in vitro differentiation of immunocompetent human dendritic cells from CD14(+) precursors. Blood 96 (2000) 210-217
38. Covic A., Mardare N.G., Ionita-Radu F., Totolici C., Tuţǎ L., Golea O., et al. Analysis of safety and efficacy of pegylated-interferon alpha-2a in hepatitis C virus positive hemodialysis patients: results from a large, multicenter audit. J Nephrol 19 (2006) 794-801
39. De Bruijn I., Meyer I., Gerez L., Nauta J., Giezeman K., and Palache B. Antibody induction by virosomal, MF59-adjuvanted, or conventional influenza vaccines in the elderly. Vaccine 26 (2007) 119-127